SMi announce that registration is now open to attend the 13th installment in the Drug Design conference series.

LONDON, UNITED KINGDOM, October 1, 2013 /EINPresswire.com/ -- SMi are pleased to announce that registration is now open to attend the 13th annual Advances and Progress in Drug Design conference, convening in Central London on Monday 17 and Tuesday 18 February 2014.

Advances and Progress in Drug Design will focus on new approaches and will offer attendees the chance to hear from leading industry experts on lead optimisation strategies, Structure Based Drug Design (SBDD) and Fragment Based Drug Design (FBDD).

Past events have received positive feedback from the industry including ‘Well selected talks, stimulating atmosphere’ – Sanofi, ‘Very good interactive meeting, overall excellent’ – Pfizer and ‘a very good meeting – right number of people’ - AstraZeneca

The 13th instalment in the Drug Design conference series will build upon the reputation and success of previous events and bring together a unique mix of senior executives from all over industry and academia for problem-solving, discussion and debate.

The conference will aim to:

• Understand pharma's current and future drug design strategies and highlight the challenges the industry is currently facing
• Explore the latest approaches in structure-based drug design
• Evaluate lead optimisation strategies
• Consider the latest in fragment based drug discovery as the future of drug design
• Linking HTS and FBDD - examining alternative approaches in drug discovery
• Hold two post conference interactive workshops hosted by Vernalis on New Approaches in ‘Fragment Based Approach to Lead Discovery’, and the 2nd hosted by The Research Network on ‘Chemically Modified Biologicals’
• Peer to peer networking with two morning coffee breaks, two networking lunches, two afternoon tea sessions and a networking drinks reception hosted by Chemical Computing Group on end of day one.

Key Speakers for 2014 include:

• John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
• Sudharsan Sridharan, Scientist, MedImmune
• Tom Heightman, Senior Director, Astex Pharmaceuticals
• Amaury Ernesto Fernandez-Montalvan, Lab Head, High Throughput Screening, Bayer HealthCare Pharmaceuticals
• Karl-Heinz Baringhaus, Head of R&D, Sanofi-Aventis
• Andreas Kuglstatter, Head of Protein Crystallography, Roche Chemische Unternehmungen AG
• Dr Neil Press, Director, Novartis
• Paul Labute, CEO, Chemical Computing Group
• Andrea Bortolato, Senior Computational Chemistry, Heptares Therapeutics
• Paul Brennan, Group Head/PI, Nuffield Department of Medicine


13th Annual Advances and Progress in Drug Design
Delivering practical solutions to drug discovery challenges

17-18 February, 2014,
Marriott Regents Park Hotel, London UK

For further information visit www.drug-design.co.uk

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.